Skip to main content
For laboratory research use only. Not for human or veterinary use.
Buy 2, Get 2 Free on marked vials · up to 10 free →
Supplier Evaluation·6 min read

How to evaluate a peptide supplier — a buyer's checklist

Twelve questions every research customer should ask a peptide supplier before placing the first order, and what each answer reveals about the vendor's quality posture.

The research peptide market has no industry-wide quality certification, so evaluation falls to the buyer. Three areas separate suppliers: supply-chain transparency about where material is made, documentation rigour including third-party per-lot COAs, and compliance posture. A vague answer in any one of them is itself the answer.

By the Bench Grade Research Team ·

The research peptide supply market is fragmented and largely unregulated at the small-vendor scale. There is no industry-wide quality certification, no required disclosure standard, and a wide range of operating practices that all use similar marketing language. The practical defense for a research customer is a structured evaluation checklist applied to every new supplier before the first order. This guide walks through twelve questions that, taken together, distinguish a serious supplier from a marketing-first reseller.

Supply-chain transparency

  1. Where is the peptide synthesized? A real answer names a country and ideally a city. "Manufactured in our facility" without geography is not an answer.
  2. Where is the peptide manufactured, and who supplies the active ingredient? A supplier that does not know the answer is one or more layers removed from the actual production.
  3. Is the analyzing laboratory independent from the synthesizer and the supplier? "Independent" means a different commercial entity, not a different department.
  4. Does the supplier own the synthesis IP, or are they reselling someone else's product with their label on it? Resellers can be fine, but they cannot answer technical questions about the synthesis and they cannot react to a quality issue at the source.

Documentation rigor

  1. Is the COA per-lot, with the lot number on the document matching the vial label? Generic compound-level COAs without lot specificity are a documentation failure.
  2. Does the COA include HPLC chromatogram, MS spectrum, AAA-derived peptide content, and CAS number? Any missing element weakens the identity / purity / mass claim.
  3. Is the COA dated and signed by a named analyst at a named laboratory? Anonymous documents have no accountability.
  4. Is the COA accessible without requesting it — visible on the product page or via QR on the vial? Suppliers that require an email to receive the COA are friction-mining; the documentation should be public.

Compliance posture

  1. Does the supplier explicitly and consistently describe products as research use only? Therapeutic, dosing, or human-use language anywhere on the site collapses the RUO posture.
  2. Does the supplier require an RUO acknowledgment at checkout? A casual checkbox is the minimum; a structured attestation including researcher status, age verification, and no-human-use confirmation is the standard.
  3. Does the shipping label and packing slip include the "not for human or veterinary use" disclosure? Documentation that lives only on the website but not on the physical product is incomplete.
  4. Does the supplier publicly stand behind the COA — for instance, with a guarantee that refunds if an independent test disagrees with their published numbers? Verification you can audit yourself is stronger than verification you must trust.

What good answers look like

A supplier that scores well on all twelve questions is rare in the research peptide space — most suppliers will fail at least two or three. The pattern that matters: a supplier should answer the questions clearly, without hedging, and the answers should match what's actually visible on their site. A supplier that gives a confident answer that contradicts the public-facing documentation is mismatched between marketing and operations; that mismatch tends to surface again in product quality.

A six-step verification checklist

  1. Match the lot number. The lot number printed on the vial label should appear on the certificate. A certificate for another lot, or one with no lot number, does not describe the vial in front of you.
  2. Identify the laboratory. The certificate should name the laboratory that ran the tests. Look the laboratory up, check its accreditation (for example ISO/IEC 17025) and what that accreditation covers, and confirm the report through the laboratory's own verification route where one exists.
  3. Compare the dates. The analysis date should fall after the lot was made and before it was shipped. A certificate dated long before the lot, or after it left the supplier, describes something else.
  4. Check identity by mass spectrometry. The observed mass should agree with the expected molecular weight within the tolerance the laboratory states. A purity figure alone does not show the material is what the label says.
  5. Check the purity method. An HPLC purity figure should state the method and the detection wavelength, and the chromatogram should be attached. A number with no method and no trace cannot be checked.
  6. Know how you would re-test. Decide which accredited laboratory you would send a sealed vial to, which tests you would ask for (identity by mass spectrometry, purity by HPLC), and what the supplier commits to in writing if the result disagrees.

What a COA cannot tell you

A Certificate of Analysis reports what one laboratory measured, on one sample, on one date, by the methods it names. It cannot tell you:

  • How the vial was stored and shipped after the sample was tested.
  • Whether every vial in the lot matches the sample the laboratory received.
  • Net peptide content, unless it was measured separately: HPLC area-percent purity is not the same measurement.
  • Contaminants the listed methods do not detect, such as residual solvents, endotoxin or heavy metals, unless those tests are reported.
  • Whether the material suits a particular experimental design.

Bench Grade's answers to the twelve questions

Our peptides are made in the USA from vetted domestic and international API, and verified per lot in an independent US laboratory whose name appears on every COA. Per-lot COAs include HPLC chromatogram with integrated peaks, ESI-MS with theoretical and observed masses, AAA-derived peptide content by mass, and CAS number. The COA is published at benchgradepeptides.com/coa and reachable via QR on every vial. The RUO posture appears on every page (site banner), every product page, every shipping label, and a structured acknowledgment is required at checkout. The Bench Grade Guarantee refunds the order, the test, the shipping, and adds $100 if an independent third-party lab disagrees with our published numbers. The full breakdown is at /guarantee.

References

Primary literature for the compounds discussed above. Links open the record on PubMed.

  1. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2) Davies M, et al. Lancet. 2021. PMID 33667417 → · summary
  2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, et al. N Engl J Med. 2021. PMID 34170647 → · summary
  3. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3) Wadden TA, et al. JAMA. 2021. PMID 33625476 → · summary
  4. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, et al. N Engl J Med. 2021. PMID 33567185 → · summary
  5. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Sikiric P, et al. Curr Pharm Des. 2018. PMID 29998800 → · summary
  6. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Marso SP, et al. N Engl J Med. 2016. PMID 27295427 → · summary
  7. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, et al. N Engl J Med. 2016. PMID 27633186 → · summary
  8. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management Pi-Sunyer X, et al. N Engl J Med. 2015. PMID 26132939 → · summary
Not sure which compound applies?
Where the research goes after the fundamentals
For people who have already optimised the basics and want the primary literature rather than another beginner guide.

Primary sources

Frequently asked questions

What should I ask a peptide supplier before ordering?
Where the API is synthesised, who performs the testing, whether COAs are per-lot or per-product, whether the chromatogram is published, and what the counter-ion is. Each has a correct, specific answer; hedging on any of them is informative.
Is a per-product COA acceptable instead of per-lot?
No. A per-product COA describes a batch you did not receive. Synthesis varies between lots, which is the entire reason lot numbers exist. The document should name the lot in your hand.
How do I verify a supplier's testing is independent?
The COA should carry the testing laboratory's name and be traceable to it. If the only signature is the seller's, the material has been self-certified.

Compounds discussed in this guide

More on supplier evaluation

All products discussed in this guide are supplied by Bench Grade Peptides for laboratory research use only. Not for human or veterinary use.

Browse the catalog